Matheus Sewastjanow-Silva

20PUBLICATIONS
46CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Oral and maxillofacial surgeryPredictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jul 28, 2026
Perioperative Nivolumab and Ipilimumab with Chemotherapy and Chemoradiation for Resectable Gastric and Gastroesophageal Junction Adenocarcinoma: A Phase 1/2 Non-Randomized Clinical Trial.

|Jul 02, 2026
North American Delphi Consensus Study on Sinonasal Malignancy Survivorship Care.

|Apr 01, 2026
Symptom Burden and Healthcare Resource Use in Patients With Claudin 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Retrospective Review.

Matheus Sewastjanow-Silva, Mok Oh, Lawrence Chang

|Feb 19, 2026
Sustained Response to Lorlatinib and Pemetrexed in ALK Fusion-Positive Anaplastic Thyroid Carcinoma With Multiple Distant Metastases: A Case Report.

Matheus Sewastjanow-Silva, Maria E Cabanillas, Eduardo Andreazza Dal Lago

|Nov 18, 2025
Chemotherapy alone for stage II-IVa laryngeal squamous cell carcinoma: A 20-year follow-up.

Mateus Trinconi Cunha, Matheus Sewastjanow-Silva, F Christopher Holsinger

|Nov 17, 2025
Microvascular Free Tissue Transfer for Reconstruction of Anterior Skull Base Defects.

Thomas Townes, Edward I Chang, Matheus Sewastjanow-Silva

Pageof 4

Frequent Collaborators

3 joint publications

Ahmed Abdelhakeem

3 joint publications

Linghua Wang

3 joint publications

Jane E Rogers

2 joint publications

Kohei Yamashita